References
- Hoffman P C, Bitran J D, Golomb H M. Chemotherapy of metastatic non small cell bronchogenic carcinoma. Sem Oncol 1983; 10: 111–122
- Casazza A M, Di Marco A, Bonadonna G, et al. Effect of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubi-cin and doxorubicin. Anthracyclines: Current Status and New Developments. Academic Press, New York 1980; 403–430
- Casazza A M. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979; 63: 835–844
- Casazza A M, Bertazzoli C, Pratesi G, et al. Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin (4-DMD) in mice. Proc Am Assoc Cancer Res and ASCO 1979; 20: 16
- Di Marco A, Casazza A M, Pratesi G. Antitumor activity of 4-demethoxy-daunorubicin administered orally. Cancer Treat Rep 1977; 61: 893–894
- Mountain C F. A new international staging system for lung cancer. Chest (Suppl) 1986; 89: 225–233
- Miller A B, Hoogstraten B, Staquet M, et al. Reporting result of cancer treatment. Cancer 1981; 47: 207–214
- Joss R A, Obrecht J P, Alberto P, et al. Phase II trial of 4-demethoxydaunorubicin in patient with non small cell lung cancer. Cancer Treat Rep 1984; 68: 563–564
- Broggini M, Italia C, Columbo T, et al. Activity and distribution of IV and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 1984; 68: 739–747
- Kriss M G, Gralla R J, Kelsen D P, et al. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer. Am J Clin Oncol 1985; 8: 377–379